Solventum (SOLV) vs peers
SOLV's EV/Sales is 2.4x, compared with 6.7x at the middle of 8 peers.
Health Care. Updated .
| Stock | EV/Sales | Own 5-year rank |
|---|---|---|
| SOLVSolventum | 2.4x | 60% |
| LLYLilly (Eli) | 14.8x | 49% |
| ABBVAbbVie | 8.7x | 100% |
| AMGNAmgen | 7.4x | 93% |
| GILDGilead Sciences | 7.0x | 98% |
| TMOThermo Fisher Scientific | 6.4x | 93% |
| MRKMerck & Co. | 6.3x | 99% |
| PFEPfizer | 3.5x | 71% |
| UNHUnitedHealth | 0.9x | 26% |
How to read this comparison
Same-industry coverage is limited. These are up to eight covered companies in the same sector, largest market value first.
EV/Sales divides enterprise value (stock market value plus debt, less cash) by revenue from the previous twelve months. The middle peer reading excludes SOLV and unavailable values.
Own 5-year rank compares each stock with its available weekly readings within the last five years. At least 26 usable weeks are required. A rank of 20% means its current multiple is above 20% of its past readings. It is not a rank against the other stocks in this table.
Dates show data updates; the latest available weekly observation can differ between stocks. Different growth rates, margins and financial risks can explain different multiples. Missing or non-positive denominators are left unranked.